Corpus Intelligence IC Memo — TRINITAS HOSPITAL 2026-04-26 04:02 UTC
IC Memo — TRINITAS HOSPITAL
Investment Committee Memorandum | NJ | 192 beds | Grade C | EBITDA uplift $18.9M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

TRINITAS HOSPITAL

CCN 310027 | UNION, NJ | 192 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

TRINITAS HOSPITAL is a 192-bed under-performing / distressed in UNION, NJ with $256.4M in net patient revenue and a -27.3% operating margin. The hospital serves a payer mix of 17.3% Medicare, 13.7% Medicaid, and 69.0% commercial.

Thesis: Undervalued. Our ML models identify $18.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -27.3% to -20.0% (+736bps).

Net Revenue HCRIS$256.4M
Current EBITDA COMPUTED$-70.1M
Operating Margin COMPUTED-27.3%
Occupancy HCRIS58.3%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS18.8%
Distress Probability ML47.0%

2. Market Context & Competitive Position

95
NJ Hospitals
-3.9%
State Median Margin
53
Comparable Hospitals

NJ has 95 Medicare-certified hospitals with a median operating margin of -3.9%. The target's margin of -27.3% places it below the state median. Among 53 size-comparable peers (96-384 beds), the median margin is -3.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (96-384), prioritizing same-state peers. 53 hospitals in the comp set.

HospitalStateBedsRevenueMargin
TRINITAS HOSPITAL (Target)NJ192$256.4M-27.3%
ENGLEWOOD HOSPITAL & MED CTRNJ292$967.3M0.1%
CAPITAL HEALTH MED CENTER - HONJ209$746.8M0.8%
UH - UNIVERSITY HOSPITALNJ358$702.0M-27.5%
JFK UNIVERSITY MEDICAL CENTERNJ351$688.7M-6.8%
PRINCETON HEALTHCARE SYSTEMNJ206$587.8M-5.7%
ST. PETERS UNIVERSITY HOSPITALNJ352$543.0M1.9%
INSPIRA MEDICAL CENTER VINELANNJ280$505.5M-12.0%
HOLY NAME HOSPITALNJ289$493.4M8.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $18.9M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.4M+210bp18mo
Cost to Collect4.5%2.5%$5.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$5.1M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.1M+122bp9mo
Clean Claim Rate88.0%96.0%$164K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.4M
Cost to Collect
$5.1M
Denial Rate Reduction
$5.1M
A/R Days Reduction
$3.1M
Clean Claim Rate
$164K
Total EBITDA Uplift$18.9M
Current EBITDA$-70.1M
+ RCM Uplift+$18.9M
Pro Forma EBITDA$-51.2M
Current Margin-27.3%
Pro Forma Margin-20.0%
WC Released (1x)$9.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-107.9M$-273.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-107.9M$-336.2M0.00x-100.0%
Bull Case9.0x11.0x$-97.1M$-309.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-97.1M$-365.8M0.00x-100.0%
Bear Case11.0x10.0x$-118.7M$-333.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-118.7M$-405.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 53 hospitals with 96-384 beds
  • Same-state prioritization (n=54)
  • Comp margins: P25=-18.0% / P50=-3.9% / P75=2.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.